SINO BIOPH.SUBDIV.HD-,025
SINO BIOPH.SUBDIV.HD-,025/ KYG8167W1380 /
SMZ1
6/14/2024 12:15:25 PM
|
Chg.
+0.0188
|
Volume |
Bid1:58:19 PM |
Ask1:35:18 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
0.3407EUR
|
+5.84%
|
21,350 Turnover: 7,274.0050 |
0.3304Bid Size: 3,060 |
0.3433Ask Size: 58,000 |
6.11 bill.EUR |
- |
- |
Business description
Sino Biopharmaceutical Limited, together with its subsidiaries, is a research and development driven pharmaceutical conglomerate in the Republic of China. Its business encompasses a fully integrated chain in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumours, liver disease, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopedic diseases. In order to enhance our sustainable competitiveness, the Group attaches great importance to R&D breakthroughs and is positioned as an industry leader in terms of R&D expenditures and product innovation.
Management board & Supervisory board
CEO |
Tse Eric SY |
Management board |
Li Chunling, Theresa Tse, Tse Hsin, Chen,Sean, Ben Toogood, Jin Song, George Orphanides |
Supervisory board |
Cheng Cheung Ling, Theresa Tse, Tse, Eric S Y, Tse Hsin, Tian Zhoushan, Li Mingqin, Lu Zhengfei, Li Dakui, Lu Hong, Zhang Lu Fu, LI Kwok Tung Donald |
Company data
Name: |
Sino Biopharmaceutical Ltd. |
Address: |
Rm 4109, Office Tower, Convention Plaza, 1 Harbour Road,Wanchai, Hong Kong |
Phone: |
+852-2802-9886 |
Fax: |
+852-2880-0847 |
E-mail: |
info@sino-biopharm.com
|
Internet: |
www.sinobiopharm.com |
Industry: |
Biotechnology |
Sector: |
Biotechnology |
Sub sector: |
Biotechnology |
End of financial year: |
12/31 |
Free Float: |
51.86% |
IPO date: |
12/8/2003 |
Investor relations
Name: |
- |
IR phone: |
- |
IR Fax: |
- |
IR e-mail: |
-
|
Company calendar
CW 27 | 7/5/2024
Dividend Payment
|